Guardant Health, Inc. (GH), Tuesday announced that the company's Shield multi-cancer detection or MCD test, a methylation-based blood test for the multi-cancer screening, has been granted Breakthrough Device designation from the U.S. Food and Drug Administration.
The designation comes as Shield MCD test was chosen by the National Cancer Institute for the Vanguard Study, where the test demonstrated strong performance in predicting the presence of cancers and cancer tissue of origin.
Following this recognition, the company expects to collaborate with FDA and other stakeholders to bring the Shield MCD test to the patients.
In the pre-market hours, GH is trading at $43, up 2.14 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.